Candotti F. Clinical Manifestations and Pathophysiological Mechanisms of the Wiskott-Aldrich Syndrome. J Clin Immunol. 2018 Jan. 38 (1):13-27. [QxMD MEDLINE Link].
Sullivan KE, Mullen CA, Blaese RM, Winkelstein JA. A multiinstitutional survey of the Wiskott-Aldrich syndrome. J Pediatr. 1994 Dec. 125(6 Pt 1):876-85. [QxMD MEDLINE Link].
Snapper SB, Rosen FS. The Wiskott-Aldrich syndrome protein (WASP): roles in signaling and cytoskeletal organization. Annu Rev Immunol. 1999. 17:905-29. [QxMD MEDLINE Link].
Kwan SP, Hagemann TL, Radtke BE, et al. Identification of mutations in the Wiskott-Aldrich syndrome gene and characterization of a polymorphic dinucleotide repeat at DXS6940, adjacent to the disease gene. Proc Natl Acad Sci U S A. 1995 May 9. 92(10):4706-10. [QxMD MEDLINE Link].
Yin HL, Stull JT. Proteins that regulate dynamic actin remodeling in response to membrane signaling minireview series. J Biol Chem. 1999 Nov 12. 274(46):32529-30. [QxMD MEDLINE Link].
Haddad E, Zugaza JL, Louache F, et al. The interaction between Cdc42 and WASP is required for SDF-1-induced T- lymphocyte chemotaxis. Blood. 2001 Jan 1. 97(1):33-8. [QxMD MEDLINE Link].
Snapper SB, Meelu P, Nguyen D, et al. WASP deficiency leads to global defects of directed leukocyte migration in vitro and in vivo. J Leukoc Biol. 2005 Mar 17. Epub:[QxMD MEDLINE Link].
Westerberg L, Larsson M, Hardy SJ, et al. Wiskott-Aldrich syndrome protein deficiency leads to reduced B-cell adhesion, migration, and homing, and a delayed humoral immune response. Blood. 2005 Feb 1. 105(3):1144-52.
Zhang H, Schaff UY, Green CE, Chen H, Sarantos MR, Hu Y. Impaired integrin-dependent function in Wiskott-Aldrich syndrome protein-deficient murine and human neutrophils. Immunity. 2006 Aug. 25(2):285-95. [QxMD MEDLINE Link].
Remold-O'Donnell E, Rosen FS. Sialophorin (CD43) and the Wiskott-Aldrich syndrome. Immunodefic Rev. 1990. 2(2):151-74. [QxMD MEDLINE Link].
Huang W, Ochs HD, Dupont B, et al. The Wiskott-Aldrich syndrome protein regulates nuclear translocation of NFAT2 and NF-kappaB (RelA) independently of its role in filamentous actin polymerization and actin cytoskeletal rearrangement. J Immunol. 2005 Mar 1. 174(5):2602-11. [QxMD MEDLINE Link].
Ochs HD, Notarangelo LD. Structure and function of the Wiskott-Aldrich syndrome protein. Curr Opin Hematol. 2005 Jul. 12(4):284-91. [QxMD MEDLINE Link].
Notarangelo LD, Notarangelo LD, Ochs HD. WASP and the phenotypic range associated with deficiency. Curr Opin Allergy Clin Immunol. 2005 Dec. 5(6):485-90. [QxMD MEDLINE Link].
Ochs HD, Thrasher AJ. The Wiskott-Aldrich syndrome. J Allergy Clin Immunol. 2006 Apr. 117(4):725-38; quiz 739. [QxMD MEDLINE Link].
Anton IM, Jones GE. WIP: a multifunctional protein involved in actin cytoskeleton regulation. Eur J Cell Biol. 2006 Apr. 85(3-4):295-304. [QxMD MEDLINE Link].
de la Fuente MA, Sasahara Y, Calamito M, et al. WIP is a chaperone for Wiskott-Aldrich syndrome protein (WASP). Proc Natl Acad Sci U S A. 2007 Jan 16. 104(3):926-31. [QxMD MEDLINE Link].
Konno A, Kirby M, Anderson SA, Schwartzberg PL, Candotti F. The expression of Wiskott-Aldrich syndrome protein (WASP) is dependent on WASP-interacting protein (WIP). Int Immunol. 2007 Feb. 19(2):185-92. [QxMD MEDLINE Link].
Calle Y, Anton IM, Thrasher AJ, Jones GE. WASP and WIP regulate podosomes in migrating leukocytes. J Microsc. 2008 Sep. 231(3):494-505. [QxMD MEDLINE Link].
Ramesh N, Geha R. Recent advances in the biology of WASP and WIP. Immunol Res. 2008 Nov 19. [QxMD MEDLINE Link].
Soderling SH, Scott JD. WAVE signalling: from biochemistry to biology. Biochem Soc Trans. 2006 Feb. 34(Pt 1):73-6. [QxMD MEDLINE Link].
Takenawa T, Suetsugu S. The WASP-WAVE protein network: connecting the membrane to the cytoskeleton. Nat Rev Mol Cell Biol. 2007 Jan. 8(1):37-48. [QxMD MEDLINE Link].
H Pauker M, Reicher B, Joseph N, Wortzel I, Jakubowicz S, Noy E, et al. WASp Family Verprolin-Homologous Protein-2 (WAVE2) and Wiskott-Aldrich Syndrome Protein (WASp) Engage in Distinct Downstream Signaling Interactions at the T Cell Antigen Receptor Site. J Biol Chem. 2014 Oct 23. [QxMD MEDLINE Link].
Westerberg LS, Dahlberg C, Baptista M, et al. Wiskott-Aldrich syndrome protein (WASP) and N-WASP are critical for peripheral B cell development and function. Blood. 2012 Mar 12. [QxMD MEDLINE Link].
Ryser O, Morell A, Hitzig WH. Primary immunodeficiencies in Switzerland: first report of the national registry in adults and children. J Clin Immunol. 1988 Nov. 8(6):479-85. [QxMD MEDLINE Link].
Abuzakouk M, Feighery C. Primary Immunodeficiency Disorders in the Republic of Ireland: First Report of the National Registry in Children and Adults. J Clin Immunol. 2005 Jan. 25(1):73-77. [QxMD MEDLINE Link].
Perry GS 3d, Spector BD, Schuman LM, et al. The Wiskott-Aldrich syndrome in the United States and Canada (1892- 1979). J Pediatr. 1980 Jul. 97(1):72-8. [QxMD MEDLINE Link].
Mullen CA, Anderson KD, Blaese RM. Splenectomy and/or bone marrow transplantation in the management of the Wiskott-Aldrich syndrome: long-term follow-up of 62 cases. Blood. 1993 Nov 15. 82(10):2961-6. [QxMD MEDLINE Link].
Syrigos KN, Makrilia N, Neidhart J, et al. Prolonged survival after splenectomy in Wiskott-Aldrich syndrome: a case report. Ital J Pediatr. 2011 Sep 10. 37:42. [QxMD MEDLINE Link]. [Full Text].
Kobayashi R, Ariga T, Nonoyama S, Kanegane H, Tsuchiya S, Morio T. Outcome in patients with Wiskott-Aldrich syndrome following stem cell transplantation: an analysis of 57 patients in Japan. Br J Haematol. 2006 Nov. 135(3):362-6. [QxMD MEDLINE Link].
Pai SY, DeMartiis D, Forino C, Cavagnini S, Lanfranchi A, Giliani S. Stem cell transplantation for the Wiskott-Aldrich syndrome: a single-center experience confirms efficacy of matched unrelated donor transplantation. Bone Marrow Transplant. 2006 Nov. 38(10):671-9. [QxMD MEDLINE Link].
Shin CR, Kim MO, Li D, et al. Outcomes following hematopoietic cell transplantation for Wiskott-Aldrich syndrome. Bone Marrow Transplant. 2012 Mar 19. [QxMD MEDLINE Link].
Parolini O, Ressmann G, Haas OA, et al. X-linked Wiskott-Aldrich syndrome in a girl. N Engl J Med. 1998 Jan 29. 338(5):291-5. [QxMD MEDLINE Link].
Lanzi G, Moratto D, Vairo D, et al. A novel primary human immunodeficiency due to deficiency in the WASP-interacting protein WIP. J Exp Med. 2012 Jan 16. 209(1):29-34. [QxMD MEDLINE Link]. [Full Text].
Buckley RH. Primary Immunodeficiency Diseases. Middleton E Jr, Reed CE, Ellis EF, Adkinson NF Jr, Yunginger JW, Busse WW, eds. Allergy: Principles and Practice. 5th ed. St. Louis, Mo: Mosby-Year Book; 1998. Vol 2: 713-34.
Dupuis-Girod S, Medioni J, Haddad E, et al. Autoimmunity in Wiskott-Aldrich syndrome: risk factors, clinical features, and outcome in a single-center cohort of 55 patients. Pediatrics. 2003 May. 111(5 Pt 1):e622-7. [QxMD MEDLINE Link].
Peacocke M, Siminovitch KA. Wiskott-Aldrich syndrome: new molecular and biochemical insights. J Am Acad Dermatol. 1992 Oct. 27(4):507-19. [QxMD MEDLINE Link].
Senapati J, Devasia AJ, David S, Manipadam MT, Nair S, Jayandharan GR, et al. Diffuse large B cell lymphoma in wiskott-Aldrich syndrome: a case report and review of literature. Indian J Hematol Blood Transfus. 2014 Sep. 30:309-13. [QxMD MEDLINE Link]. [Full Text].
Ochs HD. Mutations of the Wiskott-Aldrich Syndrome Protein affect protein expression and dictate the clinical phenotypes. Immunol Res. 2008 Dec 11. [QxMD MEDLINE Link].
Schwaber J, Rosen FS. X chromosome linked immunodeficiency. Immunodefic Rev. 1990. 2(3):233-51. [QxMD MEDLINE Link].
Akman IO, Ostrov BE, Neudorf S. Autoimmune manifestations of the Wiskott-Aldrich syndrome. Semin Arthritis Rheum. 1998 Feb. 27(4):218-25. [QxMD MEDLINE Link].
Ochs HD, Slichter SJ, Harker LA, et al. The Wiskott-Aldrich syndrome: studies of lymphocytes, granulocytes, and platelets. Blood. 1980 Feb. 55(2):243-52. [QxMD MEDLINE Link].
Schwartz M, Mibashan RS, Nicolaides KH, et al. First-trimester diagnosis of Wiskott-Aldrich syndrome by DNA markers [letter]. Lancet. 1989 Dec 9. 2(8676):1405. [QxMD MEDLINE Link].
Kenney DM. Wiskott-Aldrich syndrome and related X-linked thrombocytopenia. Curr Opin Pediatr. 1990. 2:931-4.
Buckley RH. Advances in the correction of immunodeficiency by bone marrow transplantation. Pediatr Ann. 1987 May. 16(5):412-3, 416-21. [QxMD MEDLINE Link].
Filipovich AH, Stone JV, Tomany SC, et al. Impact of donor type on outcome of bone marrow transplantation for Wiskott-Aldrich syndrome: collaborative study of the International Bone Marrow Transplant Registry and the National Marrow Donor Program. Blood. 2001 Mar 15. 97(6):1598-603. [QxMD MEDLINE Link].
Knutsen AP, Steffen M, Wassmer K, et al. Umbilical cord blood transplantation in Wiskott Aldrich syndrome. J Pediatr. 2003 May. 142(5):519-23. [QxMD MEDLINE Link].
Ochs HD, Filipovich AH, Veys P, Cowan MJ, Kapoor N. Wiskott-Aldrich syndrome: diagnosis, clinical and laboratory manifestations, and treatment. Biol Blood Marrow Transplant. 2008 Jan. 15(1 Suppl):84-90. [QxMD MEDLINE Link].
Parkman R, Rappeport J, Geha R, et al. Complete correction of the Wiskott-Aldrich syndrome by allogeneic bone-marrow transplantation. N Engl J Med. 1978 Apr 27. 298(17):921-7. [QxMD MEDLINE Link].
Boztug K, Dewey RA, Klein C. Development of hematopoietic stem cell gene therapy for Wiskott-Aldrich syndrome. Curr Opin Mol Ther. 2006 Oct. 8(5):390-5. [QxMD MEDLINE Link].
Galy A, Roncarolo MG, Thrasher AJ. Development of lentiviral gene therapy for Wiskott Aldrich syndrome. Expert Opin Biol Ther. 2008 Feb. 8(2):181-90. [QxMD MEDLINE Link].
Frecha C, Toscano MG, Costa C, Saez-Lara MJ, Cosset FL, Verhoeyen E. Improved lentiviral vectors for Wiskott-Aldrich syndrome gene therapy mimic endogenous expression profiles throughout haematopoiesis. Gene Ther. 2008 Jun. 15(12):930-41. [QxMD MEDLINE Link].
Marangoni F, Bosticardo M, Charrier S, Draghici E, Locci M, Scaramuzza S, et al. Evidence for Long-term Efficacy and Safety of Gene Therapy for Wiskott-Aldrich Syndrome in Preclinical Models. Mol Ther. 2009 Mar 3. [QxMD MEDLINE Link].
Bosticardo M, Ferrua F, Cavazzana M, Aiuti A. Gene therapy for wiskott-Aldrich syndrome. Curr Gene Ther. 2014. 14(6):413-21. [QxMD MEDLINE Link].
Scaramuzza S, Biasco L, Ripamonti A, et al. Preclinical Safety and Efficacy of Human CD34(+) Cells Transduced With Lentiviral Vector for the Treatment of Wiskott-Aldrich Syndrome. Mol Ther. 2012 Feb 28. [QxMD MEDLINE Link].
Galy A, Thrasher AJ. Gene therapy for the Wiskott-Aldrich syndrome. Curr Opin Allergy Clin Immunol. 2011 Dec. 11(6):545-50. [QxMD MEDLINE Link].
Astrakhan A, Sather BD, Ryu BY, et al. Ubiquitous high-level gene expression in hematopoietic lineages provides effective lentiviral gene therapy of murine Wiskott-Aldrich Syndrome. Blood. 2012 Mar 19. [QxMD MEDLINE Link].
Hacein-Bey Abina S, Gaspar HB, Blondeau J, Caccavelli L, Charrier S, et al. Outcomes following gene therapy in patients with severe Wiskott-Aldrich syndrome. JAMA. 2015 Apr 21. 313 (15):1550-63. [QxMD MEDLINE Link].
Litzman J, Jones A, Hann I, et al. Intravenous immunoglobulin, splenectomy, and antibiotic prophylaxis in Wiskott-Aldrich syndrome. Arch Dis Child. 1996 Nov. 75(5):436-9. [QxMD MEDLINE Link].
Lum LG, Tubergen DG, Corash L, Blaese RM. Splenectomy in the management of the thrombocytopenia of the Wiskott-Aldrich syndrome. N Engl J Med. 1980 Apr 17. 302(16):892-6. [QxMD MEDLINE Link].
Conley ME, Notarangelo LD, Etzioni A. Diagnostic criteria for primary immunodeficiencies. Representing PAGID (Pan-American Group for Immunodeficiency) and ESID (European Society for Immunodeficiencies). Clin Immunol. 1999 Dec. 93(3):190-7. [QxMD MEDLINE Link].
Winkelstein JA, Fearon E. Carrier detection of the X-linked primary immunodeficiency diseases using X-chromosome inactivation analysis. J Allergy Clin Immunol. 1990 Jun. 85(6):1090-7. [QxMD MEDLINE Link].
Conley ME, Saragoussi D, Notarangelo L, et al. An international study examining therapeutic options used in treatment of Wiskott-Aldrich syndrome. Clin Immunol. 2003 Dec. 109(3):272-7. [QxMD MEDLINE Link].
Friedrich W, Schutz C, Schulz A, Benninghoff U, Honig M. Results and long-term outcome in 39 patients with Wiskott-Aldrich syndrome transplanted from HLA-matched and -mismatched donors. Immunol Res. 2008 Oct 10. [QxMD MEDLINE Link].
Grabenstein JD. Immune Globulin Intravenous (Human). ImmunoFacts: Vaccines & Immunologic Drugs. Conshohocken, Pa: Wolters Kluwer Health (Facts and Comparisons); 1999. 212-24b.
Guill MF, Brown DA, Ochs HD, et al. IgM deficiency: clinical spectrum and immunologic assessment. Ann Allergy. 1989 Jun. 62(6):547-52. [QxMD MEDLINE Link].
Hobbs JR, Milner RD, Watt PJ. Gamma-M deficiency predisposing to meningococcal septicaemia. Br Med J. 1967 Dec 9. 4(579):583-6. [QxMD MEDLINE Link].
National Institutes of Health Consensus Conference. Intravenous immunoglobulin. Prevention and treatment of disease. JAMA. 1990 Dec 26. 264(24):3189-93. [QxMD MEDLINE Link].
Park JY, Shcherbina A, Rosen FS, et al. Phenotypic perturbation of B cells in the Wiskott-Aldrich syndrome. Clin Exp Immunol. 2005 Feb. 139(2):297-305. [QxMD MEDLINE Link].
Sorensen RU, Tomford JW, Gyves MT, et al. Use of intravenous immune globulin in pregnant women with common variable hypogammaglobulinemia. Am J Med. 1984 Mar 30. 76(3A):73-7. [QxMD MEDLINE Link].
Taha S, Kindzelskii AL, Petty HR. Neutrophils Metabolic Oscillations in Wiskott-Aldrich Syndrome. J Allergy Clin Immunol. 2000. 105 (part 1 of 2):S217.
Yocum MW, Strong DM, Chusid MJ, Lakin JD. Selective immunoglobulin M (IgM) deficiency in two immunodeficient adults with recurrent staphylococcal pyoderma. Am J Med. 1976 Apr. 60(4):486-94. [QxMD MEDLINE Link].